BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

Rhea-AI Summary

BioMarin (NASDAQ: BMRN) will host a conference call and webcast on Monday, May 4, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update. Alexander Hardy, president and CEO, will host the call.

Dial-in and replay numbers are provided and a live audio webcast and one-week replay will be available via the investor site: https://investors.biomarin.com/.

News Market Reaction – BMRN

+1.18%

+1.18% Session close to close

In the Apr 27 session, BMRN gained 1.18%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the schedule for BioMarin’s first quarter 2026 financial results call on May ...

Analysis

This announcement sets the schedule for BioMarin’s first quarter 2026 financial results call on May 4, 2026 at 4:30 p.m. ET, continuing its pattern of regular quarterly communications. Historical earnings call notices under the same tag have produced modest average moves of about 1.41%. Investors may focus on how upcoming results align with prior 2025 revenues of $3.22B, 2026 guidance ranges, and integration of recent acquisitions.

Key Figures

2025 total revenue: $3.22B Q4 2025 revenue: $875M VOXZOGO revenue: $927M +5 more

8 metrics

2025 total revenue $3.22B Full-year 2025, up 13% year-over-year

Q4 2025 revenue $875M Fourth quarter 2025, up 17% year-over-year

VOXZOGO revenue $927M Full-year 2025 product revenue, up 26%

Enzyme Therapies revenue $2.105B Full-year 2025 segment revenue, up 9%

2026 revenue guidance $3.325–3.425B Total revenues guidance for 2026, excluding Amicus

2026 EPS guidance $4.95–5.15 Non-GAAP diluted EPS guidance for 2026, excluding Amicus

Amicus acquisition value $4.8B All-cash agreement to acquire Amicus Therapeutics

Inozyme acquisition value $270M Completed acquisition of Inozyme Pharma

Previous Conferences,earnings Reports

5 past events · Latest: Feb 17 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Earnings call notice	Neutral	+0.1%	Announced Q4 and full-year 2025 results call and webcast timing.
Jul 22	Earnings call notice	Neutral	+4.7%	Scheduled Q2 2025 financial results call with webcast access details.
Apr 17	Earnings call notice	Neutral	+0.6%	Set date and time for Q1 2025 financial results call and update.
Feb 05	Earnings call notice	Neutral	+2.1%	Announced Q4 2024 and full-year 2024 results call and webcast details.
Oct 16	Earnings call notice	Neutral	-0.4%	Announced Q3 2024 financial results call with replay information.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Scheduling earnings calls and webcasts has historically led to modest, mostly positive price reactions, suggesting these notices are treated as routine but slightly constructive catalysts.

Recent Company History

Recent news for BioMarin highlights steady operational progress and recurring communication around financial results. Prior conference call scheduling announcements in 2024 and 2025 produced small mostly positive moves between roughly flat and mid-single digits. Alongside this, the company has reported growing revenues, product data, regulatory approvals, and strategic transactions. Today’s announcement of a Q1 2026 results call fits this established pattern of routine investor communications ahead of detailed earnings releases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN RAFAEL, Calif., April 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a general business update.

Dial-in Number
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 3424435 

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 3424435  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with a portfolio of commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.  

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(650) 374-2803

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-may-4-2026-at-430pm-et-302753431.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) discuss its first quarter 2026 results?

The call is scheduled for Monday, May 4, 2026 at 4:30 p.m. ET. According to the company, Alexander Hardy will host and provide a general business update alongside the Q1 2026 financial results.

How can investors join the BioMarin (BMRN) May 4, 2026 conference call?

Investors can join via toll-free dial-in or international numbers and a live audio webcast. According to the company, the webcast is accessible through https://investors.biomarin.com/ in the investor relations section.

What are the dial-in and replay details for the BioMarin (BMRN) earnings call?

Primary U.S./Canada dial-in is 800-715-9871 and international dial-in is 646-307-1963. According to the company, replay numbers and a playback ID will be provided and archived for one week after the call.

Will BioMarin (BMRN) provide a webcast and how long will the replay be available?

Yes. A live audio webcast will be available and a replay will be archived for one week after the call. According to the company, the webcast and replay can be accessed via the investor site at investors.biomarin.com.

Who will host the BioMarin (BMRN) first quarter 2026 conference call?

Alexander Hardy, BioMarin's president and CEO, will host the call. According to the company, he will discuss first quarter 2026 financial results and provide a general business update during the May 4, 2026 webcast.